

## POSITION PAPER

# The Bronchodilator and Anti-Inflammatory Effect of Long-Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper

I. Agache<sup>1</sup>  | I. M. Adcock<sup>2</sup>  | C. A. Akdis<sup>3</sup>  | M. Akdis<sup>3</sup> | G. Bentabol-Ramos<sup>4</sup> | M. van den Berge<sup>5</sup> | C. Boccabella<sup>6</sup>  | W. G. Canonica<sup>7,8</sup> | C. Caruso<sup>9</sup>  | M. Couto<sup>10</sup>  | I. Davila<sup>11</sup> | D. Drummond<sup>12</sup> | J. Fonseca<sup>13</sup> | A. Gherasim<sup>14</sup>  | S. del Giacco<sup>15</sup> | D. J. Jackson<sup>16</sup>  | M. Jutel<sup>17,18</sup>  | A. Licari<sup>19</sup> | S. Loukides<sup>20</sup>  | A. Moreira<sup>21,22,23</sup> | M. Mukherjee<sup>24</sup>  | I. Ojanguren<sup>25</sup> | O. Palomares<sup>26</sup>  | A. Papi<sup>27</sup>  | L. Perez de Llano<sup>28</sup>  | O. J. Price<sup>29,30</sup>  | M. Rukhazde<sup>31,32</sup> | M. H. Shamji<sup>33,34</sup>  | D. Shaw<sup>35</sup>  | S. Sanchez-Garcia<sup>36</sup> | A. Testera-Montes<sup>37</sup> | M. J. Torres<sup>37</sup>  | I. Eguiluz-Gracia<sup>37</sup> 

**Correspondence:** I. Eguiluz-Gracia ([iboneguiluz@gmail.com](mailto:iboneguiluz@gmail.com))

**Received:** 30 August 2024 | **Revised:** 5 November 2024 | **Accepted:** 4 December 2024

**Funding:** This Position Paper was supported by the European Academy of Allergy and Clinical Immunology (EAACI) under the EAACI Task force on the Anti-inflammatory Effect of Long-acting Muscarinic Antagonists in Asthma from the Asthma Section [Budget code: 40005] (years 2022–2024).

**Keywords:** acetylcholine | asthma | bronchodilator | endotype | long-acting muscarinic antagonists | precision medicine

## ABSTRACT

As cholinergic innervation is a major contributor to increased vagal tone and mucus secretion, inhaled long-acting muscarinic antagonists (LAMA) are a pillar for the treatment of chronic obstructive pulmonary disease and asthma. By blocking the muscarinic receptors expressed in the lung, LAMA improve lung function and reduce exacerbations in asthma patients who remained poorly controlled despite treatment with inhaled corticosteroids and long-acting  $\beta_2$  agonists. Asthma guidelines recommend LAMA as a third controller to be added on before the initiation of biologicals. In addition to bronchodilation, LAMA also exert anti-inflammatory and anti-fibrotic effects by inhibiting muscarinic receptors present in neutrophils, macrophages, fibroblasts and airway smooth muscle cells. Thus, besides bronchodilation, LAMA might provide additional therapeutic effects, thereby supporting an endotype-driven approach to asthma management. The Position Paper, developed by the Asthma Section of the European Academy of Allergy and Clinical Immunology, discusses the main cholinergic pathways in the lung, reviews the findings of significant clinical trials and real-life studies on LAMA use in asthma, examines the placement of these drugs in asthma clinical guidelines, and considers the potential for personalised medicine with LAMA in both adult and paediatric asthma patients.

## 1 | Introduction

Asthma is an environmentally driven chronic inflammatory airway disease displaying a significant heterogeneity in terms of pathophysiology, severity and evolution [1]. Inhaled

corticosteroids (ICS) are the cornerstone of asthma treatment in all severity steps, as they block most inflammatory mechanisms elicited by environmental stressors [2]. Asthma guidelines recommend increasing the ICS dose from low to medium in case of insufficient control [3–5]. Moreover, the combination of ICS

**Abbreviations:** ACh, acetylcholine; AEC, airway epithelial cell; BHR, bronchial hyperresponsiveness; BMI, body mass index; ChAT, choline acetyl transferase; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; EAACI, European Academy of Allergy and Clinical Immunology; EGF, epithelial growth factor; GINA, Global Initiative for Asthma; GLY, glycopyrronium bromide; GM-CSF, granulocyte and monocyte colony-stimulating factor; ICS, inhaled corticosteroids; LABA, long-acting  $\beta_2$  agonist; LAMA, long-acting muscarinic antagonist; LTB<sub>4</sub>, leukotriene B<sub>4</sub>; M, muscarinic; MITT, triple therapy with multiple inhaler devices; NAEPP, National Asthma Education and Prevention Program; OCS, oral corticosteroids; PG, prostaglandin; QoL, quality of life; s, allergen-specific; SIT, triple therapy with single single-inhaler device; SMC, smooth muscle cell; TIO, tiotropium bromide; TT, triple therapy; TXA<sub>2</sub>, thromboxane A<sub>2</sub>.

For affiliations refer to page 11.

with an inhaled bronchodilator, as both controller and reliever medication, is advised from the first treatment step to simultaneously alleviate inflammation and limit bronchoconstriction. In recent years, guidelines favoured the use of formoterol in this respect, as it is a  $\beta_2$  agonist with both a fast onset of action and long duration of effect [3]. More recently, several large-scale clinical trials have shown that inhaled long-acting muscarinic antagonists (LAMA) provide additional bronchodilation and protection from exacerbations in asthma patients who remain poorly controlled with ICS/long-acting  $\beta_2$  agonist (LABA) [6–9]. Therefore, tiotropium (TIO) was approved for patients with asthma  $\geq 6$  years, whereas glycopyrronium (GLY) is indicated in patients  $\geq 18$  years (Table 1). LAMA inhibit acetylcholine (ACh) signalling through the G protein-coupled muscarinic receptors expressed in the lung, thus interfering with the actions of the parasympathetic nervous system [10]. LAMA have been a pillar of chronic obstructive pulmonary disease (COPD) treatment for decades [11], where ACh-driven bronchoconstriction is the main reversible component of airflow limitation [12]. Conversely, both decreased adrenergic stimulation and enhanced muscarinic activation are prominent inducers of bronchoconstriction in asthmatics [13]. Thus, in those patients who remain insufficiently controlled with ICS/LABA, asthma guidelines recommend adding-on LAMA, before conducting a phenotypic assessment to decide on a personalised management strategy with biologicals or other targeted therapies [3–5]. This Position Paper by the Asthma Section of the European Academy of Allergy and Clinical Immunology (EAACI) describes the major neuronal and non-neuronal cholinergic pathways in the lung, together with the anti-inflammatory and anti-remodelling effect of muscarinic inhibition in airway diseases. The available evidence support LAMA clinical efficacy and provide further opportunities for an endotype-driven approach to asthma management.

## 2 | The Heterogeneity of Asthma Endotypes

In most patients with asthma, airway inflammation arises from mixed exposure (coined as the exposome) to airborne allergens, indoor and outdoor pollutants, microbes, and several other environmental stressors such as extreme weather events [14]. These environmental stimuli trigger both stromal cell-dependent and hematopoietic cell-dependent inflammation, which translates into airflow obstruction and bronchial hyperresponsiveness (BHR), via the dysregulation of adrenergic and cholinergic innervation [1]. ACh signalling in airway epithelial cells (AEC), fibroblasts and smooth muscle cells (SMC) induces fibrosis and remodelling without concomitant infiltration by hematopoietic cells [12]. Stimulation of the muscarinic receptors on innate lymphoid cells and myeloid dendritic cells activates adaptive T1, T3 or T2 immune responses (dominated by IFN $\gamma$ , IL-8/IL-17 and IL-4/IL-5/IL-13, respectively), including the synthesis of allergen-specific (s)IgG and sIgE by infiltrating B cells [15]. These inflammatory events can drive bronchoconstriction indirectly, via the inhibition of adrenergic receptors [13]. Regardless of the involvement of adaptive immune responses, eosinophils and neutrophils are recruited to the airways, under the influence of IL-5 and IL-8, respectively [16]. Cholinergic stimulation of hematopoietic and stromal cells further augments granulocyte recruitment [12]. Airway remodelling arises from the effects of the mediators produced by recruited and bronchial

resident cells [17]. In this regard, sIgG can trigger the degranulation of neutrophils, whereas sIgE activates resident mast cells and eosinophils, leading to the release of preformed mediators like proteases [1].

The features of the immune response driven by stromal and hematopoietic cells and of the neural dysregulation do not differ substantially between allergic and non-allergic asthmatics [17]. The diversity of mechanisms elicited by environmental exposures in the airways has been recently highlighted in the new EAACI Nomenclature of Allergic Diseases [18]. In this regard, it is logical to believe that the relative contribution of these mechanisms varies across the asthma population, and that this heterogeneity accounts for the different disease theratypes [19]. Inflammatory events elicited by environmental stressors in asthma patients are summarised in Figure 1.

## 3 | The Relevance of the Acetylcholine/Muscarinic Axis in Asthma Pathogenesis





The vagus nerve connects the central nervous system with the parasympathetic airway ganglion where it releases ACh. In the synaptic cleft, this neurotransmitter binds to the nicotinic or muscarinic (M) 1 receptor expressed in postjunctional parasympathetic fibres [20]. In turn, these nerves stimulate lung cells expressing M1, M2 or M3 receptors. Of note, both stromal and hematopoietic cells can respond to parasympathetic neurotransmitters [21]. M1 and M3 activation in submucosal glands induces mucus secretion, whereas M3 stimulation in SMC drives bronchoconstriction [20]. Vagal and parasympathetic fibres also express M2 receptors in the areas exposed to the synaptic cleft, so ACh can be recaptured in an autocrine manner, with subsequent blocking of the stimulation of postjunctional nerves or target cells [22]. Moreover, unmyelinated C fibres connect the central nervous system with the sub-epithelial region of the bronchial mucosa, where they are activated by physical stimuli such as heat or cold [21]. Stimulated C fibres secrete neurokinins, which promote neurotransmission in the airway ganglion (peripheral reflex arch). As the neuronal cholinergic system is one of the main regulators of airway homeostasis (Figure 2), dysfunction can lead to significant alterations resulting in different asthma endotypes [20].

### 3.1 | Regulation of Airway Smooth Muscle Tone by Muscarinic Receptors in Asthma Patients


Airway SMC from the trachea and large bronchi express large numbers of M2 and M3 receptors [20]. Although M2 is more abundant, M3 receptor signalling is the main driver of ACh-mediated bronchoconstriction in the large airways, as illustrated by the lack of response to methacholine provocation in M3 knocked-out mice [23].

Patients with asthma are more sensitive to M3 receptor signalling as compared to healthy subjects, partially due to an enhanced ability to open large Ca<sup>2+</sup> channels in SMC [24]. The intracellular signalling molecules include phospholipase C $\beta$ 1, 1,4,5-trisphosphate, CD38 and cyclic adenosine diphosphate ribose. Although the activation threshold of Ca<sup>2+</sup> channels

**TABLE 1** | Available LAMA molecules.

|                            |                                                                                                                                                             |                                                                                     |                                                                                                                                                                                                                                                                                                                                  |                                                                                                                        |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|
|                            |                                                                          |  |                                                                                                                                                                                                                                                 |                                       |
| Metabolism                 | Acclidinium bromide                                                                                                                                         | Umeclidinium bromide                                                                | Tiotropium bromide                                                                                                                                                                                                                                                                                                               | Glycopyrronium bromide                                                                                                 |
| Half-life (hours)          | Hydrolysis                                                                                                                                                  | CYP2D6                                                                              | CYP2D6 CYP3A4                                                                                                                                                                                                                                                                                                                    | Unknown                                                                                                                |
| Approval (Europe)          | 5–8<br>COPD                                                                                                                                                 | 11<br>COPD                                                                          | 27–45<br>COPD<br>Asthma                                                                                                                                                                                                                                                                                                          | 33–57<br>COPD<br>Asthma                                                                                                |
| Dose per inhalation (µg)   | 322–340                                                                                                                                                     | 55                                                                                  | 46–9                                                                                                                                                                                                                                                                                                                             | 18–2.5                                                                                                                 |
| LABA combination           | Formoterol                                                                                                                                                  | Vilanterol                                                                          | Olodaterol                                                                                                                                                                                                                                                                                                                       | Indacaterol                                                                                                            |
| Triple therapy combination | —                                                                                                                                                           | Fluticasone furoate + Vilanterol                                                    | —                                                                                                                                                                                                                                                                                                                                | Mometasone furoate + Indacaterol<br>Beclomethasone dipropionate<br>Formoterol fumarate<br>Budesonide +<br>Formoterol + |
| Inhalation device          | Genuair                                                                                                                                                     | Ellipta                                                                             | Respimat<br>Zonda<br>Handihaler<br>Glenmark                                                                                                                                                                                                                                                                                      | Breezhaler<br>Nexthaler<br>Aerosphere<br>MDI                                                                           |
| Pharmacological features   | Faster onset of action than tiotropium<br>Rapidly hydrolysed in plasma to two major inactive metabolites resulting in a low and transient systemic exposure | Slower dissociation from M3 receptor as compared with M1 and M2 receptors           | Significantly more rapid onset of action than other molecules<br>It preferentially binds to M3 over M2 receptors<br>The anticholinergic effects are primarily limited to the airways, thereby reducing systemic adverse events<br>Shorter absolute dissociation time at both M2 and M3 receptors than acclidinium and tiotropium |                                                                                                                        |

Abbreviations: COPD, chronic obstructive pulmonary disease; CYP, cytochrome; LABA, long-acting beta2 sympathomimetic; LAMA, long-acting muscarinic antagonist; MDI, metered-dose inhaler.




**FIGURE 1** | Mechanisms elicited by environmental stressors in asthma patients. Allergens can activate tissue-dependent, innate immune system-dependent and adaptive immune system-dependent mechanisms.


may be intrinsically decreased in asthmatics, several cytokines (IL-1 $\beta$ , IL-13, TNF $\alpha$  or IFN $\gamma$ ) are known to potentiate this effect [25].

ACh signalling in SMC also increases contractility by Ca<sup>2+</sup>-independent mechanisms. M2- and M3-receptor activation blocks the function of myosin light chain phosphatase, thus promoting actin cytoskeletal dynamics and bronchoconstriction [26]. This effect is mediated by the increased activity of RhoA/Rho kinase cascade pathway which is also stimulated by exposure to allergens, bacteria and cigarette smoke [26].

Increased ACh availability also accounts for M1 and M3 heightened signalling in asthmatics. ACh is synthesised in vagal or parasympathetic fibres by the enzyme choline acetyltransferase (ChAT), the expression of which is boosted by prostaglandins (PG) or thromboxane A2 (TXA2) [27]. Conversely, ACh is metabolised in the synaptic cleft by acetylcholinesterase, an enzyme that is inhibited by allergen exposure [28]. Moreover, the ability of presynaptic M2 receptor to recapture ACh is decreased in asthmatics exposed to several environmental triggers. For example, major basic proteins released from eosinophils recruited to the airways upon allergen- or ozone-induced inflammation compete with ACh to bind to M2 receptors in the synaptic clefts [29]. Similarly, neuraminidases and IFN $\gamma$  produced during viral



**FIGURE 2** | Neuronal cholinergic system in the airways. The vagus nerve connects the central nervous system with the airway ganglion, where cholinergic neurotransmission takes place. Subsequently, parasympathetic fibres stimulate smooth muscle cells and submucosal glands in the airways. Cholinergic neurotransmission in the airway ganglion is enhanced by neurokinins released from unmyelinated C fibres. ACh, Acetylcholine; M, Muscarinic; NACHR, Nicotinic acetylcholine receptor.



**FIGURE 3** | Cholinergic control of bronchial smooth muscle tone in asthma patients. Asthmatics display intrinsic abnormalities in the contractility of smooth muscle cells. These alterations arise from calcium-dependent and calcium-independent mechanisms. Increased availability of acetylcholine in the synaptic cleft also accounts for cholinergic bronchoconstriction. In this regard, many environmental stressors can either promote acetylcholine synthesis or decrease acetylcholine metabolism. ACh, Acetylcholine; AChE, Acetylcholinesterase; cADPR, Cyclic adenosine diphosphate ribose; ChAT, Choline acetyltransferase; IFN, Interferon; IL, Interleukin; IP<sub>3</sub>, 1,4,5-trisphosphate; M, Muscarinic; MBP, Major basic protein; MLCP, Myosin light chain phosphatase; PG, Prostaglandin; PLCβ<sub>1</sub>, Phospholipase Cβ<sub>1</sub>; SMC, Smooth muscle cell; TNF, Tumour necrosis factor; TXA<sub>2</sub>, Thromboxane A<sub>2</sub>.

infections cleave M2 receptor and prevent the recapture of ACh [30]. In this regard, asthmatics are more responsive to antimuscarinic bronchodilation during viral infections than during steady state [31].

The epithelial barrier defect in patients with asthma facilitates the interaction between sub-epithelial C fibres and the environmental stressors [32]. C fibres respond with the production of neurokinins, which boosts the release of histamine, PG, TXA<sub>2</sub> or bradykinin to the airway ganglion, and favours M1 receptor activation in the postjunctional parasympathetic fibre [33]. Figure 3 depicts the mechanisms driving cholinergic bronchoconstriction in asthma patients.

### 3.2 | Regulation of Mucus Secretion by Muscarinic Receptors in Asthmatics

Airway mucus is a heterogeneous gelatinous mix of secretions and cell debris that facilitates homeostatic clearance of external agents from the lumen. Goblet cells and submucosal glands are the primary source of the secretions. Besides water (98%) and electrolytes (1%), secretions contain glycoproteins like mucins, especially MUC5AC and MUC5B [34]. These glycopolymers are held together by disulphide bonds and contribute substantially to the viscosity of airway mucus [34]. As submucosal glands from the trachea and large bronchi express high amounts of M1 and M3 receptors, ACh is the main driver of mucus secretion in the central airways [35]. Isolated M3 signalling stimulates mucin secretion, whereas the co-activation of M1 and M3 receptors results in the release of water and electrolytes by submucosal glands [36]. Conversely, direct goblet cell stimulation in the central airways requires relatively high amounts of ACh [37], which probably implies a minor role for this pathway in physiological conditions.

Asthma patients have an altered mucus composition with increased MUC5AC and additional mucin types, together with less abundant water and electrolytes [38]. Moreover, M1 and M3 stimulations in submucosal glands transactivate the receptor for epithelial growth factor (EGF) in goblet cells, making them more sensitive to EGF-mediated goblet cell hyperplasia and mucus hypersecretion [39]. Thus, ACh pathway indirectly contributes to goblet cell alterations in asthma patients.

### 3.3 | Regulation of Airway Inflammation and Remodelling by Muscarinic Receptors

Hematopoietic cells infiltrating the asthmatic airways express ChAT and can synthesise ACh, while their exposure to inflammatory milieu upregulates the expression of muscarinic receptors [40]. Indeed, the non-neuronal cholinergic system is believed to regulate airway inflammation in an autocrine/paracrine manner. For example, major basic protein from eosinophils favours ACh release, which in turn activates group 2 innate lymphoid cells, thus furthering eosinophil activation [41, 42]. Airway lymphocytes also express M1–M3 receptors, although high inter-individual variability exists [43]. The activation of M3 receptors on CD8+ T cells enhances their cytotoxicity and cytokine production, whereas cholinergic stimulation in T and B cells promotes their proliferation [44]. M1 receptors are present in airway mast cells and eosinophils, while neutrophils, macrophages and monocytes display M1–M3 receptor expression [45]. ACh promotes the activation of intracellular MAP kinases in macrophages and neutrophils, leading to leukotriene (LT) B<sub>4</sub> synthesis and chemotaxis of hematopoietic cells [46]. Bronchial stromal cells also express ChAT and muscarinic receptors. M1/M3 receptor activation in AEC triggers the release of LTB<sub>4</sub> among other chemotactic factors for eosinophils, monocytes and neutrophils [47]. Moreover, the stimulation of

nicotinic receptors in AEC increases granulocyte and monocyte colony-stimulating factor (GM-CSF) production [48]. Thus, the epithelial cholinergic system becomes a potent initiator of inflammatory responses.

Besides promoting contractility, the M3 receptor activation enhances the expression of IL-6, IL-8 and cyclooxygenase 1, and the responsiveness to mitogenic factors such as EGF in SMC [49]. Moreover, M2 and M3 signalling in mesenchymal cells trigger the expression of contractile proteins via RhoA/Rho kinase and phosphoinositide 3 kinase pathways, a crucial step in their maturation into SMC [50]. Of note, this effect is driven by allergen exposure, due to its capacity to release ACh from airway stromal cells [51]. Interestingly, ACh stimulation also induces directly the proliferation of airway fibroblasts [52]. Of note, sub-epithelial fibrosis, extracellular matrix deposition and SMC hyperplasia are cardinal features of airway remodelling in asthma [53]. Together with the ability to induce goblet cell hyperplasia and mucus secretion, this evidence indicates the relevance of non-neuronal cholinergic system in airway remodelling [54]. The effects of cholinergic stimulation on mucus secretions, airway inflammation and remodelling in asthma patients are detailed in Figure 4.

#### 4 | In Vivo and In Vitro Data Showing the Anti-Inflammatory Effect of LAMA


A multitude of animal studies, especially mouse models of asthma/COPD exacerbations triggered by bacterial or viral infections, demonstrate the anti-inflammatory effects of LAMA [43, 55–59]. Collectively, these models show a reduction of inflammatory mediators and cells in the bronchoalveolar lavage fluid following treatment with LAMA [60].

Numerous in vitro studies described anti-inflammatory effects of LAMA on primary or immortalised human AEC [61]. TIO (100 nM) and acclidinium were able to suppress tobacco

smoke-induced production of IL-8 by AEC [62]. Moreover, TIO attenuated IL-8 and NF- $\kappa$ B expression on human AEC following their incubation with IL-17A or sputum from COPD patients [63]. TIO also reduced the production of chemokines (e.g. CCL2) by AEC after their incubation with TGF $\beta$ 1, ACh or sputum from COPD individuals [64]. Interestingly, TIO concentrations similar to those usually seen in the sera of patients taking 18  $\mu$ g/day suppressed the release of IL-1 $\beta$ , IL-6 and IL-8 induced by rhinoviruses in AEC sampled from healthy subjects and from patients with asthma or COPD [65]. Similarly, the LPS-triggered production of IL-8 and expression of NF- $\kappa$ B was inhibited by TIO in cultured epithelial cells [66]. Moreover, TIO reduced the secretion of IL-8 by human lung fibroblasts following their stimulation by IL-1 $\beta$ , TGF $\beta$ 1 or cholinergic drugs [64].

Importantly, TIO (30 nM), but not ipratropium bromide, reduced the activation of neutrophils (TNF $\alpha$  secretion, and expression of adhesion molecules) following their incubation with the supernatant of cultures of LPS-stimulated lung macrophages [67]. Moreover, TIO increased the apoptosis of CD3+ and CD8+ T cells in peripheral blood of COPD patients, while inhibiting the release of IL-5 and IL-13, but not IL-4, following the bacterial stimulation of peripheral mononuclear cells from asthmatics [65]. Conversely, the synthesis of GM-CSF, IL-6, IL-8 and LTB4 by neutrophils following their incubation with sputum from COPD subjects was not suppressed by TIO [68].

The evidence of the anti-inflammatory effect of LAMA other than TIO is much scarcer. In one study, GLY (100 nM) prevented both mRNA and protein expressions of IL-8 following ACh stimulation of primary AEC [67]. Bronchial provocation via histamine in patients with asthma leads to the release of IL-4, IL-5, IL-6, IL-9, IL-13, TNF $\alpha$  and TSLP in the distal airways [69]. Pre-treatment with ICS/LAMA or ICS/LABA/LAMA combinations suppressed the synthesis of these mediators and improved histamine-triggered BHR [70].



**FIGURE 4** | Cholinergic control of mucus secretion, inflammation and remodelling in asthma patients. Cholinergic stimulation increases mucus secretion by submucosal glands together with an altered mucus composition. Moreover, acetylcholine signalling also promotes goblet cell metaplasia in an indirect manner. Airway epithelial cells and most hematopoietic cells present in the airway mucosa express choline acetyltransferase together with muscarinic receptors. The activation of these receptors promotes granulocyte chemotaxis and lymphocyte proliferation by direct and indirect mechanisms. Cholinergic stimulation via muscarinic receptors drives the differentiation of mesenchymal cells into smooth muscle cells with a secretory phenotype. Moreover, acetylcholine stimulates directly bronchial fibroblasts to induce sub-epithelial fibrosis. ACh, Acetylcholine; ChAT, Choline acetyltransferase; COX-1, Cyclooxygenase 1; EGF, Epithelial growth factor; EGFR, Epithelial growth factor receptor; GM-CSF, Granulocyte and monocyte colony-stimulating factor; IL, Interleukin; IP3K, Phosphoinositide 3 kinase; LTB4, Leukotriene B4; M, Muscarinic; MUC, Mucin.

A recent systematic review identified 49 original articles examining the *in vivo* and *in vitro* effects of LAMA in patients with asthma or on human cells [22]. The collective analysis of TIO studies provided low- to medium-quality evidence for an anti-inflammatory effect of LAMA in patients with stable airway disease. A one-month TIO course (18 µg/day) suppressed LTB<sub>4</sub> release by blood neutrophils primed with GM-CSF but did not modify IL-6 and TNFα levels in the exhaled breath condensate [71]. Studies with longer treatment periods showed inconsistent results. A three-month TIO course did not change serum C-reactive protein (CRP) or blood granulocyte and monocyte counts [72], whereas a six-month course reduced blood eosinophil, neutrophil and monocyte counts without affecting CRP, TNFα or fibrinogen levels in serum [73]. Conversely, one-year TIO treatment (18 µg/day) resulted in enhanced sputum IL-8, while no change was observed for sputum IL-6 or serum CRP or IL-8 [74].

In summary, only TIO has shown clear anti-inflammatory effects in animal models of airway diseases and *in vitro* studies with human cells (mostly AEC), but definitive evidence for a clinical effect of LAMA beyond bronchodilation is still lacking in asthma patients [75].

## 5 | Clinical Data on the Efficacy of LAMA in Moderate-To-Severe Asthmatics

The co-administration of ICS, LABA and LAMA is commonly referred to as triple therapy (TT). TT regimens can be administered once or twice daily, via a single inhalation device (SITT) or through multiple inhalers (MITT) [76]. In asthma patients, SITT is associated with a higher adherence and persistence as compared to MITT [77]. Moreover, several works focusing on COPD individuals demonstrate a higher adherence and persistence, a lower rate of severe exacerbations and reductions in healthcare resource utilisation for SITT [78–80]. On the other hand, MITT has the advantage of greater flexibility when adjusting for the ICS dose [76]. In any case, adherence to both SITT and MITT is relatively low and typically decreases over 12 months [81]. Further research is warranted to assess whether once-daily SITT dosing translates into additional clinical benefits.

Four clinical trials assessed the efficacy of SITT administered in different combinations and doses versus medium- to high-dose ICS/LABA, or MITT in asthma patients [6–9]. Importantly, no significant differences in exacerbation rate were found between SITT (high-dose ICS) and high-dose ICS/LABA (same molecules) in the CAPTAIN study (fluticasone furoate plus vilanterol plus UME) [9], IRIDIUM study (mometasone furoate plus indacaterol acetate plus GLY) [7] and TRIGGER study (beclomethasone dipropionate plus formoterol plus GLY) [6]. Nevertheless, a lower number of severe exacerbations were observed for SITT, when compared with dose-matched ICS/LABA combinations with the same (TRIMARAN) [6] or different (IRIDIUM) [7] molecules. Moreover, a pooled analysis of CAPTAIN study showed that TT was associated with a higher and clinically relevant improvement in asthma control questionnaire at week 24 (63% for TT versus 55% for ICS/LABA) [9]. A recent meta-analysis pooling these trials concluded that (i) SITT with high-dose ICS

is more effective than SITT with medium-dose ICS in reducing exacerbations; (ii) SITT with medium-dose ICS is equally effective as high-dose ICS/LABA in reducing exacerbations; and (iii) SITT with medium-dose ICS improves FEV<sub>1</sub> significantly more than high-dose ICS/LABA [82].

Clinical trials assessing the efficacy of adding a LAMA to patients who remained poorly controlled on dose-matched ICS/LABA have shown an increase in FEV<sub>1</sub> as compared with placebo [83–85]. A reduction of exacerbation risk was also reported for TT by the PrimoTina-asthma study [83]. Moreover, MITT improved control and quality of life (QoL), although the minimal clinically important difference was not reached.

Interestingly, a recent study including > 12,000 adolescents and adults with uncontrolled asthma indicated that TT did not reduce disease-related hospitalisations [86]. On the other hand, the addition of TIO reduced short-acting β<sub>2</sub> agonist utilisation and improved lung function and sleep quality in school-age children receiving ICS/LABA in the context of persistent moderate asthma [87]. The safety profile of ICS/LABA/LAMA is considered favourable in adolescent and adult asthmatics [88–91]. A pairwise meta-analysis of clinical trials identified an increased risk (RR 0.74) of vascular serious adverse events for TT [90] in this population, but other studies have not confirmed this effect [91, 92]. Of note, indirect evidence from systematic reviews including both children and adults with persistent uncontrolled asthma showed that TT was associated with increased dry mouth and dysphonia (high-certainty evidence), but serious adverse events were not significantly different between active and placebo groups (moderate-certainty evidence) [92].

The results of major clinical trials of TT in asthma patients are summarised in Table 2.

## 6 | Comparative Performance of ICS/LABA/LAMA in Patients With Asthma or With COPD

As a whole, inflammation in asthma is regarded more sensitive to ICS than in COPD [2, 88]. On the other hand, cholinergic stimulation is a relevant driver of bronchoconstriction in both asthma and COPD individuals, whereas decreased adrenergic activation is more prominent in asthma than in COPD [93, 94]. Of note, the performance of LABA and LAMA as an add-on therapy to ICS in asthma patients is comparable in terms of improvement of control, exacerbation rate and need for systemic corticosteroids [93, 94]. On the other hand, LAMA perform slightly better for lung function, while LABA improves the quality of life in asthmatics [89, 94]. Thus, unlike COPD, LAMA are not recommended as monotherapy in asthma [95–97].

In patients with COPD, inhaled muscarinic antagonists or β<sub>2</sub> agonists in monotherapy are advised for mild patients with ≤1 moderate exacerbations not leading to hospitalisation in the previous year (long-acting drugs are preferred) [11]. Conversely, patients with moderate-to-severe disease, or those with ≥2 moderate exacerbations or ≥1 exacerbation leading to hospitalisation, should receive LAMA/LABA combination [98]. Of note, the addition of ICS is only encouraged in COPD individuals with frequent exacerbations and a pre-ICS blood

**TABLE 2** | Summary of studies assessing MITT or SITT efficacy in severe asthma.

| Identifier         | Study design | Intervention                                                                                               | Type of triple therapy | FEV1 and symptoms                                                                                                                                                                                                              | Exacerbations                                                                                                                                                                                                                                                  |
|--------------------|--------------|------------------------------------------------------------------------------------------------------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PrimoTIN asthma    | RCT          | ICS/LABA vs. ICS/LABA/TIO 5 µg                                                                             | MITT                   | +86 ± 34 mL in trial 1 ( $p = 0.01$ ) and +154 ± 32 mL in trial 2 ( $p < 0.001$ )<br>MCD in ACQ not achieved<br>MCD in AQLQ not achieved                                                                                       | ↓21% in the risk of a severe exacerbation (HR, 0.79; $p = 0.03$ )                                                                                                                                                                                              |
| Ohta et al. [83]   | RCT          | ICS/LABA vs. ICS/LABA/TIO (5 or 2.5 µg)                                                                    | MITT                   | +112 mL ( $p = 0.02$ )<br>MCD in ACQ not achieved                                                                                                                                                                              | N.A.                                                                                                                                                                                                                                                           |
| Kerwin et al. [84] | RCT          | ICS/LABA vs. ICS/LABA/GLY or ICS/LABA/TIO (2.5 µg)                                                         | MITT                   | No statistically significant differences between any of the arms vs. placebo in FEV <sub>1</sub><br>MCD in ACQ not achieved                                                                                                    | No significant decrease                                                                                                                                                                                                                                        |
| TRIMARAN           | RCT          | BDP/FF/GLY vs. BDP/FF (medium dose)                                                                        | SITT                   | + 57 mL (95% CI 15–99; $p = 0.0080$ )                                                                                                                                                                                          | ↓15% (RR 0.85, 95% CI 0.73–0.99; $p = 0.033$ )                                                                                                                                                                                                                 |
| TRIGGER            | RCT          | BDP/FF/GLY vs. BDP/FF (high dose)<br>BDP/FF/GLY vs. BDP/FF + TIO (high dose)                               | SITT                   | +73 mL (95% CI 26–120; $p = 0.0025$ )<br>–45 mL (95% CI –103 to 13; $p = 0.13$ )                                                                                                                                               | ↓12% (RR 0.88, 95% CI 0.75–1.03; $p = 0.11$ )<br>+7% (RR 1.07, 95% CI 0.88–1.30; $p = 0.50$ )                                                                                                                                                                  |
| IRIDIUM            | RCT          | MF/IND/GLY vs. MF/IND (medium and high doses)<br>MF/IND/GLY (medium and high doses) vs. FP/SLM (high dose) | SITT                   | +76 mL ( $p < 0.001$ ) for medium dose<br>+65 mL ( $p < 0.001$ ) for high dose<br>MCD in ACQ not achieved<br>+99 mL ( $p < 0.001$ ) for medium dose<br>+119 mL ( $p < 0.001$ ) for high dose<br>Significant improvement in ACQ | ↓13% (RR 0.87, 95% CI 0.71–1.06; $p = 0.17$ ) for medium dose<br>↓15% (RR 0.85, 95% CI 0.68–1.04; $p = 0.12$ ) for high dose<br>↓19% (RR 0.81, 95% CI 0.66–0.99; $p = 0.041$ ) for medium dose<br>↓36% (RR 0.64, 95% CI 0.52–0.78; $p < 0.001$ ) for high dose |
| ARGON              | RCT          | MF/IND/GLY (medium and high doses) vs. FP/SLM + TIO (high dose)                                            | SITT                   | High-dose MF/IND/GLY vs. FP/SLM/TIO + 96 mL ( $p < 0.001$ )<br>Medium-dose MF/IND/GLY vs. FP/SLM/TIO + 9 mL ( $p = 0.713$ )<br>AQLQ non-inferior ( $p < 0.001$ ) in all comparisons                                            | High-dose MF/IND/GLY vs. FP/SLM/TIO<br>↓12% (RR 0.88; IC 95%: 0.65; 1.19; $p = 0.414$ )<br>Medium-dose MF/IND/GLY vs. FP/SLM/TIO + 4% (RR 1.04; IC 95%: 0.77; 1.39; $p = 0.798$ )                                                                              |
| CAPTAIN            | RCT          | F/UMEC/VI<br>200/62.5/25 vs. F/VI<br>200/25F/UMEC/VI<br>100/62.5/25 vs. F/VI 100/25                        | SITT                   | +92 mL ( $p < 0.001$ ) for high dose<br>+110 mL ( $p < 0.001$ ) for medium dose<br>MCD in ACQ not achieved<br>SGRQ: no significant differences                                                                                 | No significant differences                                                                                                                                                                                                                                     |

Abbreviations: ACQ, Asthma control questionnaire; AQLQ, asthma quality of life questionnaire; BDP, beclomethasone dipropionate; F, fluticasone furoate; FEV<sub>1</sub>, forced expiratory volume in the first second; FF, formoterol furoate; GLY, glycopyrronium; HR, Hazard ratio; ICS, inhaled corticosteroids; IND, indacaterol; LABA, long-acting beta-agonist; MCD, minimum clinically important difference; MF, mometasone furoate; MITT, multiple inhaler triple therapy; N.A., Not available; RCT, randomised controlled trial; RR, relative risk; SGRQ, Saint George Respiratory Questionnaire; SITT, single-inhaler triple therapy; TIO, tiotropium; TIO, tiotropium Respimat; UME, Umeclidinium; VI, vilanterol.

eosinophil count  $\geq 300$  cells/ $\mu$ L. Indeed, TT in this population may reduce the risk of all-cause mortality [99]. LAMA improve FEV<sub>1</sub>, symptoms (dyspnoea, cough and expectoration) and QoL while reducing exacerbations, hospitalisations and death rate in COPD individuals [100]. Of note, LAMA enhance the benefits of pulmonary rehabilitation by increasing its ability to reduce symptoms and improve QoL, peripheral muscle function and exercise capacity in patients with COPD [98]. Moreover, LAMA are superior to LABA in decreasing exacerbation and hospitalisation rates in moderate-to-severe COPD patients [100]. Nevertheless, LAMA/LABA combination is still recommended in this population because both drug types modulate the bronchial tone differently and have an additive effect on the inhibition of Ca<sup>2+</sup> channels and SMC tyrosine kinases [99]. No preference for bronchodilator type is given for mild COPD patients with infrequent exacerbations, due to a high inter-patient variability in the responsiveness to these drugs [11].

The safety profile of LAMA is considered favourable in COPD individuals [101]. A slightly higher incidence (adjusted hazard ratio of 1.28 (95% CI: 1.05–1.55) relative to LABA-ICS) of major adverse cardiovascular events has been recently reported for TT [102], but this finding requires confirmation. Table 3 summarises the comparative efficacy/safety of LAMA, LABA and ICS in asthma and COPD patients.

## 7 | LAMA Positioning in Asthma Guidelines

The 2024 update of the Global Initiative for Asthma (GINA) [3] recommends adding inhaled TIO or GLY to asthma patients insufficiently controlled with medium-dose ICS/formoterol (step

5). GINA considers that TT should be advised in every patient before high-dose ICS or before the initiation of biologicals, including prior phenotypic assessment. Similarly, the addition of inhaled TIO is regarded as an intermediate step before biologicals for subjects 6–11 years insufficiently controlled with medium-dose ICS/LABA.

The Focused Updates of the Asthma Management Guidelines generated in 2020 by the National Asthma Education and Prevention Program (NAEPP) established by the US Government reviewed the evidence regarding LAMA use [5]. In patients  $\geq 12$  years, ICS/TIO is listed as an alternative to ICS/formoterol in step 3 (low-dose ICS) and step 4 (medium-dose ICS), whereas TT with medium- to high-dose ICS is advised for every individual in step 5. Conversely, LAMA is not recommended for patients 5–11 years, or adolescents and adults on OCS therapy (step 6).

The European Respiratory Society/American Thoracic Society Guideline on the Management of Severe Asthma conducted a systematic review on the use of LAMA in paediatric and adult patients in 2020 [4]. The document formulates a strong recommendation for the addition of inhaled TIO to children, adolescents and adults with severe asthma uncontrolled despite GINA steps 4–5 or NAEPP step 5 (moderate-quality evidence). Table 4 summarises the positioning of LAMA in major asthma guidelines.

## 8 | Real-Life Studies of LAMA in Severe Asthma

Published registries report that 36%–39% of severe asthmatics receive a LAMA [103–105]. In this regard, the capacity of TT to

**TABLE 3** | Comparative efficacy of ICS, LABA and LAMA in patients with asthma or COPD.

| Asthma |          |                                                                                                                                                                                         | COPD                                                                                                  |
|--------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| ICS    | Benefits | Improves lung function, quality of life and asthma control<br>Decreases exacerbation rate                                                                                               | Decreases exacerbation rate only in patients with high blood eosinophils                              |
|        | Harm     | Depends on the dose<br>Low/medium dose:<br>Oral candidiasis<br>Decreased growth in children<br>High dose:<br>Osteoporosis/bone fractures<br>Adrenal insufficiency<br>Metabolic syndrome | Severe (increased risk of osteoporosis, bone fractures and severe infections)                         |
| LABA   | Benefits | Improves lung function better than LABA. Improves quality of life and control. Benefit all patients.                                                                                    | Improves lung function, quality of life and exacerbation rate in all patients, but less than LABA.    |
|        | Harm     | Mild (tachycardia, muscle-skeletal tremor), but more frequent than LABA                                                                                                                 | Mild (tachycardia, muscle-skeletal tremor), but more frequent than LABA                               |
| LAMA   | Benefits | Improves lung function<br>Decreases exacerbation rate in patients on medium-to-high ICS/LABA<br>Decreases mucus production                                                              | Improves lung function, quality of life and symptoms, and decreases exacerbation rate in all patients |
|        | Harm     | Mild and reversible (dry mouth)                                                                                                                                                         | Mild and reversible (dry mouth)                                                                       |

reduce exacerbations as compared with dose-matched ICS/LABA regimens was reported in a large retrospective real-life cohort of 7857 patients [103] and in a real-life prospective study of 2042 asthmatics [104]. The previous smoking habit, older age, concomitant bronchiectasis and body mass index (BMI) > 30 kg/m<sup>2</sup> were associated with increased LAMA prescription in real-life studies.

## 9 | LAMA Guiding Precision Medicine in Asthma

Seventy-five percent of severe asthmatics on TT remain uncontrolled, thus leading to > 80% of severe asthmatics on biologicals receiving or having received a LAMA [105]. The relatively low success rate of LAMA in severe asthma might arise from the lack of a phenotype-guided prescription [103–105]. In this regard, patients with high total IgE in serum at baseline are less likely to respond to a three-month course of inhaled TIO [106]. In line with this, a sub-analysis of the CAPTAIN study suggests that increasing ICS dose from medium to high may especially benefit patients with elevated T2 biomarkers, whereas TT with medium-dose ICS might be a more meaningful approach to prevent exacerbations in subjects without evidence of T2 biomarkers [107]. Conversely, a post hoc analysis of PrimoTINa-asthma trial indicated that the efficacy of add-on TIO to ICS/LABA was independent of gender, BMI, disease evolution, smoking habit and FEV<sub>1</sub> reversibility [108]. Smoking habit (current vs. former) did not influence the improvement of lung function in COPD individuals treated with GLY [109]. On the other hand, a post hoc analysis of the IRIDIUM trial showed that TT benefits equally asthma patients with/without fixed airflow limitation [110].

Interestingly, M1–M3 receptors are more abundant in the central airways which might account for a higher benefit from LAMA in patients with predominant proximal airway obstruction, as compared with those with primary involvement of the distal airways [20]. The same rationale might apply for patients with increased mucus production [34–36].

Moreover, the relative importance of the vagal tone increases with age [111]. Therefore, it is tempting to speculate that asthmatics with older age, increased mucus production, exacerbations triggered by infections, decreased FEV<sub>1</sub> (as a measure of central airways obstruction) with preserved FEF<sub>25-75</sub> or other measures of the peripheral airways, and with absent T2 biomarkers are particularly good candidates for TT [112]. Table 5 shows the visible properties of an asthma patient theratype benefiting from LAMA addition.

## 10 | Knowledge Gaps and Research Needs

The evidence available from mechanistic and real-life studies points at a phenotype-specific performance for LAMA [22, 103–105]. Thus, it is crucial to investigate whether individuals with non-T2 asthma benefit better from these drugs, and how LAMA interact with other non-T2 interventions (e.g. azithromycin or bronchial thermoplasty) [113]. The impact on lung function decline and on other surrogates of remodelling deserves further evaluation. There is also a need to analyse the impact of current and former smoking habit on LAMA performance in asthmatic populations. Of note, most clinical trials of

**TABLE 4** | LAMA positioning in major asthma guidelines.

|                               | GINA 2024                  | NAEPP 2020                      | ERS/ATS 2020                        |
|-------------------------------|----------------------------|---------------------------------|-------------------------------------|
| <b>Adolescents and adults</b> |                            |                                 |                                     |
| Add-on preferred              | Medium-dose ICS/formoterol | Medium- or high-dose ICS/LABA   | Medium- or high-dose ICS/formoterol |
| Step                          | 5                          | 5                               | GINA 4–5<br>NAEPP 5                 |
| Molecule                      | TIO or GLY                 | TIO or GLY                      | TIO                                 |
| Add-on alternative            | Medium/high-dose ICS/LABA  | Low-dose ICS<br>Medium-dose ICS | No                                  |
| Step                          | 4<br>5                     | 3<br>4                          | —                                   |
| Molecule                      | TIO or GLY                 | TIO or GLY                      | —                                   |
| <b>Children 6–11 years</b>    |                            |                                 |                                     |
| Add-on preferred              | No                         | No                              | Medium-dose ICS/formoterol          |
| Step                          | —                          | —                               | GINA 5                              |
| Molecule                      | —                          | —                               | TIO                                 |
| Add-on alternative            | Medium-dose ICS/formoterol | No                              | No                                  |
| Step                          | 4                          | —                               | —                                   |
| Molecule                      | TIO                        |                                 |                                     |

Abbreviations: ATS, American Thoracic Society; ERS, European Respiratory Society; GINA, Global Initiative for Asthma; GLY, glycopyrronium bromide; ICS, inhaled corticosteroids; LABA, long-acting beta2 agonists; NAEPP, National Asthma Education and Prevention Program; TIO, tiotropium bromide.

**TABLE 5** | Visible properties of an asthmatic theratype who would benefit the most from LAMA addition.

| Domain           | Visible property                                                   |
|------------------|--------------------------------------------------------------------|
| Age              | Older age                                                          |
| Lung function    | Low FEV <sub>1</sub> with preserved FEF <sub>25-75</sub> or R25-R5 |
| Mucus production | Frequent and abundant                                              |
| Exacerbations    | Triggered by infections                                            |
| T2 biomarkers    | Low                                                                |

TT in asthmatics exclude current smokers and include only a limited number of former non-heavy smokers [6, 7, 9]. Similarly, it would be interesting to investigate if certain patients' profiles on low-to-medium ICS/LABA would improve their asthma control by adding LAMA rather than increasing the ICS dose.

The efficacy and safety of LAMA in children also require further investigation. The comparative performance of LAMA molecules needs to be tested in head-to-head trials. Similarly, the real capacity of LAMA to delay the introduction of biological in severe asthma patients needs to be established. In this regard, there is a need to analyse the long-term performance of TT and whether the delay of biologicals is harmful for patients. Overall, the unmet needs about LAMA potential in asthmatics can only be addressed by sufficiently powered clinical trials, registries and real-life studies incorporating long-term surveillance and follow-up.

## 11 | Conclusion and Final Remarks

The therapeutic arsenal for patients with asthma has been recently enlarged by the addition of LAMA, the indication of which was previously restricted to COPD. Cytokine-mediated inflammation and decreased adrenergic stimulation are major drivers of bronchoconstriction and remodelling in most asthmatics, especially in patients with T2 asthma. These traits respond relatively well to the combination of ICS and LABA. Nevertheless, patients with T2 asthma on ICS/LABA can obtain additional benefit from the blockage of muscarinic receptors. In this regard, large-scale clinical trials indicate the capacity of TT to improve lung function and decrease exacerbations in poorly controlled moderate-to-severe asthmatics. Moreover, the cholinergic system might be the main driver of bronchoconstriction, mucus secretion and remodelling in some asthma patients of varying phenotypes and severity. Indeed, some data suggest that the addition of LAMA can delay the prescription of biologicals in some individuals with severe asthma. Further studies are needed to identify the LAMA responsive theratypes, and thus to position LAMA in the personalised and cost-efficient strategies for the management of asthma patients.

### Author Contributions

I.A. and I.E.G. designed the work and distributed the tasks among the other authors. The rest of the authors performed the literature review and drafted the corresponding sections. I.A. and I.E.G. coordinated the

work of the rest of the authors and wrote the final version of the manuscript which was approved by all the authors.

### Affiliations

<sup>1</sup>Faculty of Medicine, Transylvania University, Brasov, Romania | <sup>2</sup>Airway Disease Section, National Heart and Lung Institute, Imperial College, London, UK | <sup>3</sup>Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland | <sup>4</sup>Pulmonology Unit, Hospital Regional Universitario de Malaga and IBIMA-Plataforma BIONAND, Malaga, Spain | <sup>5</sup>Department of Pulmonary Diseases, Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands | <sup>6</sup>Department of Cardiovascular and Thoracic Sciences, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli – IRCCS, Rome, Italy | <sup>7</sup>Personalized Medicine, Asthma and Allergy, Humanitas Clinical & Research Center, IRCCS, Rozzano, Italy | <sup>8</sup>Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy | <sup>9</sup>UOSD DH Internal Medicine and Digestive Disease, Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy | <sup>10</sup>Immunoallergology, Hospital CUF Trindade, Porto, Portugal | <sup>11</sup>Allergy Service, Salamanca University Hospital, Faculty of Medicine, University of Salamanca, Salamanca, Spain | <sup>12</sup>Department of Pediatric Pulmonology and Allergology, University Hospital Necker-Enfants Malades, AP-HP, Faculté de Médecine, Université Paris Cité, Inserm UMR 1138, HeKAtteam, Centre de Recherche des Cordeliers, Paris, France | <sup>13</sup>MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences, Centre for Health Technology and Services Research, Health Research Network (CINTESIS@RISE), Faculty of Medicine, University of Porto, Porto, Portugal | <sup>14</sup>ALYATEC Clinical Research Center, Strasbourg University Hospital, Strasbourg, France | <sup>15</sup>Unit of Allergy and Clinical Immunology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy | <sup>16</sup>Guy's Severe Asthma Centre, School of Immunology & Microbial Sciences, Guy's Hospital, King's College London, London, UK | <sup>17</sup>Department of Clinical Immunology, Wrocław Medical University, Wrocław, Poland | <sup>18</sup>ALL-MED Medical Research Institute, Wrocław, Poland | <sup>19</sup>Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy | <sup>20</sup>2nd Respiratory Medicine Department, "Attikon" University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece | <sup>21</sup>Department of Allergy and Clinical Immunology, Centro Hospitalar Universitário de São João, Porto, Portugal | <sup>22</sup>EPIUnit – Institute of Public Health, University of Porto, Porto, Portugal | <sup>23</sup>Laboratory for Integrative and Translational Research in Population Health (ITR), Porto, Portugal | <sup>24</sup>Department of Medicine, McMaster University & St Joseph's Healthcare, Hamilton, Ontario, Canada | <sup>25</sup>Pneumology Service, University Hospital Vall d'Hebron, VHIR, CIBERES, Autonomous University of Barcelona, Barcelona, Spain | <sup>26</sup>Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain | <sup>27</sup>Respiratory Medicine, Department of Translational Medicine, University of Ferrara, Ferrara, Italy | <sup>28</sup>Pneumology Service, Lucas Augusti University Hospital, EOXI Lugo, Monforte, Cervo, Psychiatry, Radiology, Public Health, Nursing and Medicine Department of the Santiago de Compostela University, Santiago de Compostela, Spain | <sup>29</sup>School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, UK | <sup>30</sup>Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK | <sup>31</sup>Center Allergy&Immunology, Tbilisi, Georgia | <sup>32</sup>Faculty of Medicine, Geomedi Teaching University, Tbilisi, Georgia | <sup>33</sup>National Heart and Lung Institute, Imperial College London, London, UK | <sup>34</sup>NIHR Imperial Biomedical Research Centre, London, UK | <sup>35</sup>Respiratory Research Unit, University of Nottingham, Nottingham, UK | <sup>36</sup>Allergy Unit, Hospital Infantil Universitario Niño Jesús, Madrid, Spain | <sup>37</sup>Allergy Unit, Hospital Regional Universitario de Malaga, IBIMA-Plataforma BIONAND, RICORS Inflammatory Diseases, Department of Medicine and Dermatology, Universidad de Malaga, Malaga, Spain

## Conflicts of Interest

IA, IAd, MA, GBR, MvdB, CB, CC, DD, JF, AG, SdG, MJ, AL, AM, MM, OJP, MR, DS, ATM and MJT have nothing to declare. CAA has received research grants from the Swiss National Science Foundation, European Union (EU CURE, EU Syn-Air-G), Novartis Research Institutes (Basel, Switzerland), Stanford University (Redwood City, CA), Seed Health (Boston, USA) and SciBase (Stockholm, Sweden); is Co-Chair for EAACI Guidelines on Environmental Science in Allergic diseases and Asthma; is Chair of the EAACI Epithelial Cell Biology Working Group on the Advisory Boards of Sanofi/Regeneron (Bern, Switzerland, New York, USA), Stanford University Sean Parker Asthma Allergy Center (CA, USA), Novartis (Basel, Switzerland), GSK (Zurich, Switzerland), Bristol-Myers Squibb (New York, USA), Seed Health (Boston, USA) and SciBase (Stockholm, Sweden); and is Editor-in-Chief of Allergy. GWC reports research or clinical trials grants paid to his Institution from Menarini, AstraZeneca, GSK and Sanofi-Genzyme and fees for lectures or advisory board participation from Menarini, AstraZeneca, Chiesi, FaesFarma, Firma, Genentech, Guidotti-Malesci, GSK, HAL Allergy, Innovacaremd, Novartis, OM Pharma, Red Maple, Sanofi-Aventis, Sanofi-Genzyme, Stallergenes and Uriach Pharma. ID has received payment for lectures, including service on speaker's bureaus from Allergy Therapeutics, ALK, AstraZeneca, Chiesi, Diater, GSK, Leti, Novartis and Sanofi; for a consultancy from Allergy Therapeutics, ALK-Abello, AstraZeneca, GSK, Merck, MSD, Novartis and Sanofi; and grants for Thermofisher Diagnostics, ISCIII and Junta de Castilla y León in the last three years. DJJ has received honoraria for lectures and advisory activities from GSK, Sanofi and AstraZeneca. SL has received honoraria for lectures and advisory activities from Chiesi, GSK, AstraZeneca, Menarini, Boehringer Ingelheim, Elpen and Guidotti. IO declares to have received honoraria in the last three years for participating as a speaker in meetings sponsored by AstraZeneca, Chiesi, GlaxoSmithKlein and Menarini, and as a consultant for AstraZeneca, GlaxoSmithKlein, Puretech and Sanofi. He received grants from Sanofi and GlaxoSmithKle for research projects. OP received research grants from MINECO, Ministerio de Ciencia e Innovación, Inmunotek S.L., Novartis and AstraZeneca and fees for giving scientific lectures or participation in Advisory Boards from AstraZeneca, Pfizer, GlaxoSmithKline, Inmunotek S.L., Novartis, Sanofi-Genzyme and Regeneron. MHS reports research grants from Immune Tolerance Network, Medical Research Council, Allergy Therapeutics, LETI Pharma and Rovolo Biotherapeutics and lecture fees from Allergy Therapeutics and Laboratorios Leti Pharma, all outside the submitted work. IEG has received honoraria for lectures and advisory activities from Chiesi, Gebro Pharma, Novartis, GSK, Sanofi, AstraZeneca, Abbvie, HAL Allergy, ALK, Diater, Leti Pharma, Allergopharma, Inmunotek and Viatrix. AP declares payments to his institution from Chiesi, AstraZeneca, GlaxoSmithKline and Sanofi; consultancy fees from Chiesi, AstraZeneca, GlaxoSmithKline, Sanofi, Iqvia, Avillion, Moderna, Roche, Regeneron, Zambon and Zentiva; and payment or honoraria for lectures, presentations, speakers' bureaus, from Chiesi, AstraZeneca, GlaxoSmithKline, Zambon, Sanofi, Avillion, Regeneron, Zambon and Moderna. SSG has received honoraria and lecture fees from AstraZeneca, Sanofi, GSK, Chiesi, Leti and Allergy Therapeutics. MC is an employee of Roche Pharmaceuticals but with no influence on her contribution to this article. LPdLL reports research or clinical trials grants from ASTRAZENECA, SANOFI, GSK, CHIESI and MENARINI and fees for lectures or advisory board participation from ASTRAZENECA, GSK, SANOFI, MENARINI, CHIESI, GEBRO and FAES, all outside the submitted work.

## Data Availability Statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

## References

1. I. Agache, I. Eguiluz-Gracia, C. Cojanu, et al., "Advances and Highlights in Asthma in 2021," *Allergy* 76, no. 11 (2021): 3390–3407.

2. S. H. Yeo, B. Aggarwal, S. Shantakumar, A. Mulgirigama, and P. Daley-Yates, "Efficacy and Safety of Inhaled Corticosteroids Relative to Fluticasone Propionate: A Systematic Review of Randomized Controlled Trials in Asthma," *Expert Review of Respiratory Medicine* 11, no. 10 (2017): 763–778.

3. Global Initiative for Asthma (GINA) (2024), <https://ginasthma.org/2024-report/>.

4. F. Holguin, J. C. Cardet, K. F. Chung, et al., "Management of Severe Asthma: A European Respiratory Society/American Thoracic Society Guideline," *European Respiratory Journal* 55, no. 1 (2020): 1900588.

5. M. M. Cloutier, A. P. Baptist, K. V. Blake, et al., "2020 Focused Updates to the Asthma Management Guidelines: A Report From the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group," *Journal of Allergy and Clinical Immunology* 146, no. 6 (2020): 1217–1270.

6. J. C. Virchow, P. Kuna, P. Paggiaro, et al., "Single Inhaler Extrafine Triple Therapy in Uncontrolled Asthma (TRIMARAN and TRIGGER): Two Double-Blind, Parallel-Group, Randomised, Controlled Phase 3 Trials," *Lancet* 394, no. 10210 (2019): 1737–1749.

7. H. A. M. Kerstjens, J. Maspero, K. R. Chapman, et al., "Once-Daily, Single-Inhaler Mometasone-Indacaterol-Glycopyrronium Versus Mometasone-Indacaterol or Twice-Daily Fluticasone-Salmeterol in Patients With Inadequately Controlled Asthma (IRIDIUM): A Randomised, Double-Blind, Controlled Phase 3 Study," *Lancet Respiratory Medicine* 8, no. 10 (2020): 1000–1012.

8. C. Gessner, O. Kornmann, J. Maspero, et al., "Fixed-Dose Combination of Indacaterol/Glycopyrronium/Mometasone Furoate Once-Daily Versus Salmeterol/Fluticasone Twice-Daily Plus Tiotropium Once-Daily in Patients With Uncontrolled Asthma: A Randomised, Phase IIIb, Non-inferiority Study (ARGON)," *Respiratory Medicine* 170 (2020): 106021.

9. L. A. Lee, Z. Bailes, N. Barnes, et al., "Efficacy and Safety of Once-Daily Single-Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI in Patients With Inadequately Controlled Asthma (CAPTAIN): A Double-Blind, Randomised, Phase 3A Trial," *Lancet Respiratory Medicine* 9, no. 1 (2021): 69–84.

10. T. Rheault, S. Khindri, M. Vahdati-Bolouri, A. Church, and W. A. Fahy, "A Randomised, Open-Label Study of Umeclidinium Versus Glycopyrronium in Patients With COPD," *ERJ Open Research* 2, no. 2 (2016): 00101-2015.

11. Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2024), <https://goldcopd.org/2024-gold-report/>.

12. W. Kummer and G. Krasteva-Christ, "Non-neuronal Cholinergic Airway Epithelium Biology," *Current Opinion in Pharmacology* 16 (2014): 43–49.

13. H. Kume, "Role of Airway Smooth Muscle in Inflammation Related to Asthma and COPD," *Advances in Experimental Medicine and Biology* 1303 (2021): 139–172.

14. M. Jutel, G. S. Mosnaim, J. A. Bernstein, et al., "The One Health Approach for Allergic Diseases and Asthma," *Allergy* 78, no. 7 (2023): 1777–1793.

15. J. V. Fahy, "Type 2 Inflammation in Asthma—Present in Most, Absent in Many," *Nature Reviews. Immunology* 15, no. 1 (2015): 57–65.

16. T. Ji and H. Li, "T-Helper Cells and Their Cytokines in Pathogenesis and Treatment of Asthma," *Frontiers in Immunology* 14 (2023): 1149203.

17. R. D. Britt, Jr., A. Ruwanpathirana, M. L. Ford, and B. W. Lewis, "Macrophages Orchestrate Airway Inflammation, Remodeling, and Resolution in Asthma," *International Journal of Molecular Sciences* 24, no. 13 (2023): 10451.

18. M. Jutel, I. Agache, M. Zemelka-Wiacek, et al., "Nomenclature of Allergic Diseases and Hypersensitivity Reactions: Adapted to Modern Needs: An EAACI Position Paper," *Allergy* 78, no. 11 (2023): 2851–2874.

19. G. G. Brusselle and G. H. Koppelman, "Biologic Therapies for Severe Asthma," *New England Journal of Medicine* 386, no. 2 (2022): 157–171.
20. K. S. Buels and A. D. Fryer, "Muscarinic Receptor Antagonists: Effects on Pulmonary Function," *Handbook of Experimental Pharmacology* 208 (2012): 317–341.
21. F. R. Coulson and A. D. Fryer, "Muscarinic Acetylcholine Receptors and Airway Diseases," *Pharmacology & Therapeutics* 98, no. 1 (2003): 59–69.
22. L. Calzetta, A. Coppola, B. L. Ritondo, M. Matino, A. Chetta, and P. Rogliani, "The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review," *International Journal of Chronic Obstructive Pulmonary Disease* 16 (2021): 257–279.
23. J. T. Fisher, S. G. Vincent, J. Gomez, M. Yamada, and J. Wess, "Loss of Vagally Mediated Bradycardia and Bronchoconstriction in Mice Lacking M2 or M3 Muscarinic Acetylcholine Receptors," *FASEB Journal* 18, no. 6 (2004): 711–713.
24. R. Gosens, J. Zaagsma, H. Meurs, and A. J. Halayko, "Muscarinic Receptor Signaling in the Pathophysiology of Asthma and COPD," *Respiratory Research* 7, no. 1 (2006): 73.
25. D. A. Deshpande, T. A. White, S. Dogan, T. F. Walseth, R. A. Panettieri, and M. S. Kannan, "CD38/Cyclic ADP-Ribose Signaling: Role in the Regulation of Calcium Homeostasis in Airway Smooth Muscle," *American Journal of Physiology-Lung Cellular and Molecular Physiology* 288, no. 5 (2005): L773–L788.
26. A. P. Somlyo and A. V. Somlyo, "Ca<sup>2+</sup> Sensitivity of Smooth Muscle and Nonmuscle Myosin II: Modulated by G Proteins, Kinases, and Myosin Phosphatase," *Physiological Reviews* 83, no. 4 (2003): 1325–1358.
27. R. W. Mitchell, E. Kelly, and A. R. Leff, "Reduced Activity of Acetylcholinesterase in Canine Tracheal Smooth Muscle Homogenates After Active Immune-Sensitization," *American Journal of Respiratory Cell and Molecular Biology* 5, no. 1 (1991): 56–62.
28. T. Fujii, S. Yamada, Y. Watanabe, et al., "Induction of Choline Acetyltransferase mRNA in Human Mononuclear Leukocytes Stimulated by Phytohemagglutinin, a T-Cell Activator," *Journal of Neuroimmunology* 82, no. 1 (1998): 101–107.
29. C. M. Evans, A. D. Fryer, D. B. Jacoby, G. J. Gleich, and R. W. Costello, "Pretreatment With Antibody to Eosinophil Major Basic Protein Prevents Hyperresponsiveness by Protecting Neuronal M2 Muscarinic Receptors in Antigen-Challenged Guinea Pigs," *Journal of Clinical Investigation* 100, no. 9 (1997): 2254–2262.
30. E. L. Hardaker, A. M. Bacon, K. Carlson, et al., "Regulation of TNF-Alpha- and IFN-Gamma-Induced CXCL10 Expression: Participation of the Airway Smooth Muscle in the Pulmonary Inflammatory Response in Chronic Obstructive Pulmonary Disease," *FASEB Journal* 18, no. 1 (2004): 191–193.
31. H. Kanazawa, K. Hirata, and J. Yoshikawa, "Increased Responses to Inhaled Oxitropium Bromide in Asthmatic Patients With Active Hepatitis C Virus Infection," *Chest* 125, no. 4 (2004): 1368–1371.
32. R. Berni Canani, M. Caminati, L. Carucci, and I. Eguiluz-Gracia, "Skin, Gut, and Lung Barrier: Physiological Interface and Target of Intervention for Preventing and Treating Allergic Diseases," *Allergy* 79, no. 6 (2024): 1485–1500.
33. M. Kollarik, F. Ru, N. Pavelkova, J. Mulcahy, J. Hunter, and B. J. Udem, "Role of Na(V)1.7 in Action Potential Conduction Along Human Bronchial Vagal Afferent C-Fibres," *British Journal of Pharmacology* 179, no. 2 (2022): 242–251.
34. O. W. Williams, A. Sharafkhan, V. Kim, B. F. Dickey, and C. M. Evans, "Airway Mucus: From Production to Secretion," *American Journal of Respiratory Cell and Molecular Biology* 34, no. 5 (2006): 527–536.
35. J. C. Mak and P. J. Barnes, "Autoradiographic Visualization of Muscarinic Receptor Subtypes in Human and Guinea Pig Lung," *American Review of Respiratory Disease* 141, no. 6 (1990): 1559–1568.
36. J. V. Fahy and B. F. Dickey, "Airway Mucus Function and Dysfunction," *New England Journal of Medicine* 363, no. 23 (2010): 2233–2247.
37. R. A. O'Donnell, A. Richter, J. Ward, et al., "Expression of ErbB Receptors and Mucins in the Airways of Long Term Current Smokers," *Thorax* 59, no. 12 (2004): 1032–1040.
38. K. G. Welsh, K. Rousseau, G. Fisher, et al., "MUC5AC and a Glycosylated Variant of MUC5B Alter Mucin Composition in Children With Acute Asthma," *Chest* 152, no. 4 (2017): 771–779.
39. D. A. Dartt, J. D. Rios, H. Kanno, et al., "Regulation of Conjunctival Goblet Cell Secretion by Ca(2+) and Protein Kinase C," *Experimental Eye Research* 71, no. 6 (2000): 619–628.
40. M. J. Schloss, M. Hulsmans, D. Rohde, et al., "B Lymphocyte Derived Acetylcholine Limits Steady State and Emergency Hematopoiesis," *Nature Immunology* 23, no. 4 (2022): 605–618.
41. R. W. Costello, D. B. Jacoby, G. J. Gleich, and A. D. Fryer, "Eosinophils and Airway Nerves in Asthma," *Histology and Histopathology* 15, no. 3 (2000): 861–868.
42. L. B. Roberts, R. Berkachy, M. Wane, et al., "Differential Regulation of Allergic Airway Inflammation by Acetylcholine," *Frontiers in Immunology* 13 (2022): 893844.
43. L. E. Kistemaker, I. S. Bos, M. N. Hylkema, et al., "Muscarinic Receptor Subtype-Specific Effects on Cigarette Smoke-Induced Inflammation in Mice," *European Respiratory Journal* 42, no. 6 (2013): 1677–1688.
44. S. P. Singh, N. C. Mishra, J. Rir-Sima-Ah, et al., "Maternal Exposure to Second Hand Cigarette Smoke Primes the Lung for Induction of Phosphodiesterase-4D5 Isozyme and Exacerbated Th2 Responses: Rolipram Attenuates the Airway Hyperreactivity and Muscarinic Receptor Expression but Not Lung Inflammation and Atopy," *Journal of Immunology* 183, no. 3 (2009): 2115–2121.
45. L. E. Kistemaker, S. T. Bos, W. M. Mudde, et al., "Muscarinic M3 Receptors Contribute to Allergen-Induced Airway Remodeling in Mice," *American Journal of Respiratory Cell and Molecular Biology* 50, no. 4 (2014): 690–698.
46. E. Hagforsen, A. Einarsson, F. Aronsson, K. Nordlind, and G. Michaëlsson, "The Distribution of Choline Acetyltransferase- and Acetylcholinesterase-Like Immunoreactivity in the Palmar Skin of Patients With Palmoplantar Pustulosis," *British Journal of Dermatology* 142, no. 2 (2000): 234–242.
47. M. Profita, R. D. Giorgi, A. Sala, et al., "Muscarinic Receptors, Leukotriene B4 Production and Neutrophilic Inflammation in COPD Patients," *Allergy* 60, no. 11 (2005): 1361–1369.
48. H. Klapproth, K. Racké, and I. Wessler, "Acetylcholine and Nicotine Stimulate the Release of Granulocyte-Macrophage Colony Stimulating Factor From Cultured Human Bronchial Epithelial Cells," *Naunyn-Schmiedeberg's Archives of Pharmacology* 357, no. 4 (1998): 472–475.
49. J. Kanefsky, M. Lenburg, and C. M. Hai, "Cholinergic Receptor and Cyclic Stretch-Mediated Inflammatory Gene Expression in Intact ASM," *American Journal of Respiratory Cell and Molecular Biology* 34, no. 4 (2006): 417–425.
50. A. J. Halayko, S. Kartha, G. L. Stelmack, et al., "Phosphatidylinositol-3 Kinase/Mammalian Target of Rapamycin/p70S6K Regulates Contractile Protein Accumulation in Airway Myocyte Differentiation," *American Journal of Respiratory Cell and Molecular Biology* 31, no. 3 (2004): 266–275.
51. H. W. Liu, A. J. Halayko, D. J. Fernandes, et al., "The RhoA/Rho Kinase Pathway Regulates Nuclear Localization of Serum Response

- Factor," *American Journal of Respiratory Cell and Molecular Biology* 29, no. 1 (2003): 39–47.
52. R. Gosens, M. M. GrootteBromhaar, H. Maarsingh, et al., "Bradykinin Augments EGF-Induced Airway Smooth Muscle Proliferation by Activation of Conventional Protein Kinase C Isoenzymes," *European Journal of Pharmacology* 535, no. 1–3 (2006): 253–262.
53. G. Varricchi, S. Ferri, J. Pepys, et al., "Biologics and Airway Remodeling in Severe Asthma," *Allergy* 77, no. 12 (2022): 3538–3552.
54. F. Gomes and S. L. Cheng, "Pathophysiology, Therapeutic Targets, and Future Therapeutic Alternatives in COPD: Focus on the Importance of the Cholinergic System," *Biomolecules* 13, no. 3 (2023): 476.
55. D. Domínguez-Fandos, E. Ferrer, R. Puig-Pey, et al., "Effects of Acridinium Bromide in a Cigarette Smoke-Exposed Guinea Pig Model of Chronic Obstructive Pulmonary Disease," *American Journal of Respiratory Cell and Molecular Biology* 50, no. 2 (2014): 337–346.
56. D. Toumpanakis, K. Loverdos, V. Tzouda, et al., "Tiotropium Bromide Exerts Anti-Inflammatory Effects During Resistive Breathing, an Experimental Model of Severe Airway Obstruction," *International Journal of Chronic Obstructive Pulmonary Disease* 12 (2017): 2207–2220.
57. M. Smit, A. B. Zuidhof, S. I. Bos, et al., "Bronchoprotection by Olodaterol Is Synergistically Enhanced by Tiotropium in a Guinea Pig Model of Allergic Asthma," *Journal of Pharmacology and Experimental Therapeutics* 348, no. 2 (2014): 303–310.
58. J. A. Gregory, C. Kemi, J. Ji, et al., "Effects of Tiotropium Bromide on Airway Hyperresponsiveness and Inflammation in Mice Exposed to Organic Dust," *Pulmonary Pharmacology & Therapeutics* 48 (2018): 203–210.
59. I. S. Bos, R. Gosens, A. B. Zuidhof, et al., "Inhibition of Allergen-Induced Airway Remodelling by Tiotropium and Budesonide: A Comparison," *European Respiratory Journal* 30, no. 4 (2007): 653–661.
60. A. Koarai, H. Sugiura, M. Yamada, et al., "Treatment With LABA Versus LAMA for Stable COPD: A Systematic Review and Meta-Analysis," *BMC Pulmonary Medicine* 20, no. 1 (2020): 111.
61. M. Cazzola, L. Calzetta, P. Rogliani, E. Puxeddu, F. Facciolo, and M. G. Matera, "Interaction Between Corticosteroids and Muscarinic Antagonists in Human Airways," *Pulmonary Pharmacology & Therapeutics* 36 (2016): 1–9.
62. C. H. Chen, Y. R. Li, S. H. Lin, et al., "Tiotropium/Olodaterol Treatment Reduces Cigarette Smoke Extract-Induced Cell Death in BEAS-2B Bronchial Epithelial Cells," *BMC Pharmacology and Toxicology* 21, no. 1 (2020): 74.
63. G. D. Albano, A. Bonanno, M. Moscato, et al., "Crosstalk Between mAChRM3 and  $\beta$ 2AR, via Acetylcholine PI3/PKC/PBEP1/Raf-1 MEK1/2/ERK1/2 Pathway Activation, in Human Bronchial Epithelial Cells After Long-Term Cigarette Smoke Exposure," *Life Sciences* 192 (2018): 99–109.
64. G. Anzalone, R. Gagliardo, F. Bucchieri, et al., "IL-17A Induces Chromatin Remodeling Promoting IL-8 Release in Bronchial Epithelial Cells: Effect of Tiotropium," *Life Sciences* 152 (2016): 107–116.
65. M. Profita, A. Bonanno, A. M. Montalbano, et al., " $\beta$ 2 Long-Acting and Anticholinergic Drugs Control TGF- $\beta$ 1-Mediated Neutrophilic Inflammation in COPD," *Biochimica et Biophysica Acta* 1822, no. 7 (2012): 1079–1089.
66. M. Yamaya, H. Nishimura, Y. Hatachi, et al., "Inhibitory Effects of Tiotropium on Rhinovirus Infection in Human Airway Epithelial Cells," *European Respiratory Journal* 40, no. 1 (2012): 122–132.
67. I. Suzuki, K. Asano, Y. Shikama, T. Hamasaki, A. Kanei, and H. Suzuki, "Suppression of IL-8 Production From Airway Cells by Tiotropium Bromide In Vitro," *International Journal of Chronic Obstructive Pulmonary Disease* 6 (2011): 439–448.
68. L. Costa, M. Roth, N. Miglino, et al., "Tiotropium Sustains the Anti-Inflammatory Action of Olodaterol via the Cyclic AMP Pathway," *Pulmonary Pharmacology & Therapeutics* 27, no. 1 (2014): 29–37.
69. K. Asano, Y. Shikama, N. Shoji, K. Hirano, H. Suzuki, and H. Nakajima, "Tiotropium Bromide Inhibits TGF- $\beta$ -Induced MMP Production From Lung Fibroblasts by Interfering With Smad and MAPK Pathways In Vitro," *International Journal of Chronic Obstructive Pulmonary Disease* 5 (2010): 277–286.
70. D. J. Powrie, T. M. Wilkinson, G. C. Donaldson, et al., "Effect of Tiotropium on Sputum and Serum Inflammatory Markers and Exacerbations in COPD," *European Respiratory Journal* 30, no. 3 (2007): 472–478.
71. Y. H. Lin, X. N. Liao, L. L. Fan, Y. J. Qu, D. Y. Cheng, and Y. H. Shi, "Long-Term Treatment With Budesonide/Formoterol Attenuates Circulating CRP Levels in Chronic Obstructive Pulmonary Disease Patients of Group D," *PLoS One* 12, no. 8 (2017): e0183300.
72. D. W. Perng, C. W. Tao, K. C. Su, C. C. Tsai, L. Y. Liu, and Y. C. Lee, "Anti-Inflammatory Effects of Salmeterol/Fluticasone, Tiotropium/Fluticasone or Tiotropium in COPD," *European Respiratory Journal* 33, no. 4 (2009): 778–784.
73. A. Holownia, R. M. Mroz, T. Skopinski, et al., "Tiotropium Increases Cytosolic Muscarinic M3 Receptors and Acetylated H3 Histone Proteins in Induced Sputum Cells of COPD Patients," *European Journal of Medical Research* 15 (2010): 64–67.
74. A. Benfante, F. Braidò, and N. Scichilone, "The Anti-Inflammatory Properties of Tiotropium," *Lancet Respiratory Medicine* 6, no. 8 (2018): e37.
75. R. C. Knibb, C. Alviani, T. Garriga-Baraut, et al., "The Effectiveness of Interventions to Improve Self-Management for Adolescents and Young Adults With Allergic Conditions: A Systematic Review," *Allergy* 75, no. 8 (2020): 1881–1898.
76. M. Barrecheguren, M. Monteagudo, M. Miravittles, et al., "Characteristics and Treatment Patterns of Patients With Asthma on Multiple-Inhaler Triple Therapy in Spain," *npj Primary Care Respiratory Medicine* 32, no. 1 (2022): 11.
77. W. W. Busse, C. B. Abbott, G. Germain, et al., "Adherence and Persistence to Single-Inhaler Versus Multiple-Inhaler Triple Therapy for Asthma Management," *Journal of Allergy and Clinical Immunology. In Practice* 10, no. 11 (2022): 2904–2913.
78. C. F. Vogelmeier, K. M. Beeh, M. Schultze, et al., "Evaluation of Adherence and Persistence to Triple Therapy in Patients With COPD: A German Claims Data Study," *International Journal of Chronic Obstructive Pulmonary Disease* 19 (2024): 1835–1848.
79. M. Bogart, L. G. S. Bengtson, M. G. Johnson, S. H. Bunner, N. N. Gronroos, and K. K. DiRocco, "Outcomes Following Initiation of Triple Therapy With Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy Among Medicare Advantage With Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States," *International Journal of Chronic Obstructive Pulmonary Disease* 19 (2024): 97–110.
80. L. Lin, C. Liu, W. Cheng, et al., "Comparison of Treatment Persistence, Adherence, and Risk of Exacerbation in Patients With COPD Treated With Single-Inhaler Versus Multiple-Inhaler Triple Therapy: A Prospective Observational Study in China," *Frontiers in Pharmacology* 14 (2023): 1147985.
81. P. Rogliani, B. L. Ritondo, and L. Calzetta, "Triple Therapy in Uncontrolled Asthma: A Network Meta-Analysis of Phase III Studies," *European Respiratory Journal* 58, no. 3 (2021): 2004233.
82. H. A. Kerstjens, M. Engel, R. Dahl, et al., "Tiotropium in Asthma Poorly Controlled With Standard Combination Therapy," *New England Journal of Medicine* 367, no. 13 (2012): 1198–1207.

83. K. Ohta, M. Ichinose, Y. Tohda, et al., "Long-Term Once-Daily Tiotropium Respiant<sup>®</sup> Is Well Tolerated and Maintains Efficacy Over 52 Weeks in Patients With Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study," *PLoS One* 10, no. 4 (2015): e0124109.
84. E. Kerwin, P. Dorinsky, M. Patel, et al., "A Randomized Controlled Trial of Glycopyrrolate Administered by Metered Dose Inhaler in Patients With Uncontrolled Asthma Despite ICS/LABA Treatment," *Journal of Asthma* 59, no. 7 (2022): 1420–1432.
85. N. N. Hansel, C. B. Abbott, C. M. Averell, et al., "Real-World Users of Triple Therapy for Asthma in the US," *American Journal of Managed Care* 30, no. 2 (2024): 74–81.
86. J. Huang, Y. Chen, Z. Long, X. Zhou, and J. Shu, "Clinical Efficacy of Tiotropium in Children With Asthma," *Pakistan Journal of Medical Sciences* 32, no. 2 (2016): 462–465.
87. K. Alagha, A. Palot, T. Sofalvi, et al., "Long-Acting Muscarinic Receptor Antagonists for the Treatment of Chronic Airway Diseases," *Therapeutic Advances in Chronic Disease* 5, no. 2 (2014): 85–98.
88. T. Rhen and J. A. Cidlowski, "Antiinflammatory Action of Glucocorticoids—New Mechanisms for Old Drugs," *New England Journal of Medicine* 353, no. 16 (2005): 1711–1723.
89. C. K. Billington and R. B. Penn, "Hall IP<sub>2</sub> Agonists," *Handbook of Experimental Pharmacology* 237 (2017): 23–40.
90. P. Rogliani, F. Cavalli, A. Chetta, M. Cazzola, and L. Calzetta, "Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile," *Journal of Asthma Allergy* 15 (2022): 565–577.
91. E. Scosyrev, R. van Zyl-Smit, H. Kerstjens, et al., "Cardiovascular Safety of Mometasone/Indacaterol and Mometasone/Indacaterol/Glycopyrronium Once-Daily Fixed-Dose Combinations in Asthma: Pooled Analysis of Phase 3 Trials," *Respiratory Medicine* 180 (2021): 106311.
92. L. H. Y. Kim, C. Saleh, A. Whalen-Browne, P. M. O'Byrne, and D. K. Chu, "Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma: A Systematic Review and Meta-Analysis," *Journal of the American Medical Association* 325, no. 24 (2021): 2466–2479.
93. D. M. Sobieraj, W. L. Baker, E. Nguyen, et al., "Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-Analysis," *Journal of the American Medical Association* 319, no. 14 (2018): 1473–1484.
94. K. M. Kew, D. J. Evans, D. E. Allison, and A. C. Boyter, "Long-Acting Muscarinic Antagonists (LAMA) Added to Inhaled Corticosteroids (ICS) Versus Addition of Long-Acting beta2-Agonists (LABA) for Adults With Asthma," *Cochrane Database of Systematic Reviews* 2015, no. 6 (2015): CD011438.
95. E. J. Baan, C. E. Hoeve, M. De Ridder, et al., "The ALPACA Study: (In)appropriate LAMA Prescribing in Asthma: A Cohort Analysis," *Pulmonary Pharmacology & Therapeutics* 71 (2021): 102074.
96. Y. Oba, S. Anwer, T. Maduke, T. Patel, and S. Dias, "Effectiveness and Tolerability of Dual and Triple Combination Inhaler Therapies Compared With Each Other and Varying Doses of Inhaled Corticosteroids in Adolescents and Adults With Asthma: A Systematic Review and Network Meta-Analysis," *Cochrane Database of Systematic Reviews* 12, no. 12 (2022): CD013799.
97. A. S. Melani, "Long-Acting Muscarinic Antagonists," *Expert Review of Clinical Pharmacology* 8, no. 4 (2015): 479–501.
98. C. Zhai, F. Wang, R. Xu, X. Sun, W. Ma, and L. Wang, "Umeclidinium Plus Vilanterol Versus Fluticasone Propionate Plus Salmeterol for Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized, Controlled Trials," *Postgraduate Medical Journal* 100 (2024): qgae054.
99. W. H. van Geffen, D. J. Tan, J. A. Walters, and E. H. Walters, "Inhaled Corticosteroids With Combination Inhaled Long-Acting beta2-Agonists and Long-Acting Muscarinic Antagonists for Chronic Obstructive Pulmonary Disease," *Cochrane Database of Systematic Reviews* 12, no. 12 (2023): CD011600.
100. F. Puggioni, L. Brussino, G. W. Canonica, et al., "Frequency of Tiotropium Bromide Use and Clinical Features of Patients With Severe Asthma in a Real-Life Setting: Data From the Severe Asthma Network in Italy (SANI) Registry," *Journal of Asthma and Allergy* 13 (2020): 599–604.
101. M. G. Matera, L. Calzetta, E. Puxeddu, P. Rogliani, and M. Cazzola, "A Safety Comparison of LABA+LAMA vs LABA+ICS Combination Therapy for COPD," *Expert Opinion on Drug Safety* 17, no. 5 (2018): 509–517.
102. S. Suissa, S. Dell'Aniello, and P. Ernst, "Single-Inhaler Triple Versus LABA-ICS Therapy for COPD: Comparative Safety in Real-World Clinical Practice," *Chest* (2024): S0012-3692(24)05414-X.
103. B. Chipps, G. Mosnaim, S. K. Mathur, et al., "Add-On Tiotropium Versus Step-Up Inhaled Corticosteroid Plus Long-Acting Beta-2-Agonist in Real-World Patients With Asthma," *Allergy and Asthma Proceedings* 41, no. 4 (2020): 248–255.
104. D. Price, A. Kaplan, R. Jones, et al., "Long-Acting Muscarinic Antagonist Use in Adults With Asthma: Real-Life Prescribing and Outcomes of Add-On Therapy With Tiotropium Bromide," *Journal of Asthma and Allergy* 8 (2015): 1–13.
105. L. Perez-de-Llano, G. Scelo, T. N. Tran, et al., "Exploring Definitions and Predictors of Severe Asthma Clinical Remission Post-Biologic in Adults," *American Journal of Respiratory and Critical Care Medicine* 210, no. 7 (2024): 869–880.
106. T. B. Casale, E. D. Bateman, M. Vandewalker, et al., "Tiotropium Respiant Add-On Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype," *Journal of Allergy and Clinical Immunology. In Practice* 6, no. 3 (2018): 923–935.e9.
107. H. A. Kerstjens, P. Moroni-Zentgraf, D. P. Tashkin, et al., "Tiotropium Improves Lung Function, Exacerbation Rate, and Asthma Control, Independent of Baseline Characteristics Including Age, Degree of Airway Obstruction, and Allergic Status," *Respiratory Medicine* 117 (2016): 198–206.
108. D. M. G. Halpin, E. H. Hamelmann, P. A. Frith, et al., "Comparative Responses in Lung Function Measurements With Tiotropium in Adolescents and Adults, and Across Asthma Severities: A Post Hoc Analysis," *Pulmonary Therapy* 6, no. 1 (2020): 131–140.
109. D. P. Tashkin, T. Goodin, A. Bowling, et al., "Effect of Smoking Status on Lung Function, Patient-Reported Outcomes, and Safety Among Patients With COPD Treated With Indacaterol/Glycopyrrolate: Pooled Analysis of the FLIGHT1 and FLIGHT2 Studies," *Respiratory Medicine* 155 (2019): 113–120.
110. R. N. Van Zyl-Smit, H. A. Kerstjens, J. F. Maspero, et al., "Efficacy of Once-Daily, Single-Inhaler, Fixed-Dose Combination of Mometasone/Indacaterol/Glycopyrronium in Patients With Asthma With or Without Persistent Airflow Limitation: Post Hoc Analysis From the IRIDIUM Study," *Respiratory Medicine* 211 (2023): 107172.
111. Y. Jiang, A. Yabluchanskiy, J. Deng, F. A. Amil, S. S. Po, and T. W. Dasari, "The Role of Age-Associated Autonomic Dysfunction in Inflammation and Endothelial Dysfunction," *Geroscience* 44, no. 6 (2022): 2655–2670.
112. V. Plaza, J. A. Trigueros, J. A. Carretero, et al., "The Use of Triple Therapy in Asthma. The GEMA-FORUM V Task Force," *Journal of Investigational Allergology & Clinical Immunology* 34, no. 4 (2024): 257–260.
113. M. Adrish and P. Akuthota, "Approach to Non-Type 2 Asthma," *Respiratory Medicine* 216 (2023): 107327.